LinkedIn Icon Twitter Icon
March 19-21, 2018 | Boston, MA

 

Speakers

Expand/Collapse

Michal Bassani-Sternberg
Director, Immunopeptidomics Unit at Center of Experimental Therapeutics
UNIL/CHUV

Jennifer Cochran
Department Chair, Bioengineering
Stanford University

Jochem Gokemeijer
Associate Director, Molecular Discovery Technologies
Bristol-Myers Squibb

Day Two

Wednesday, March 21 2018

09.30 | Keynote Panel Discussion: Dissecting Recent Clinical Successes and Failures to Give Greater Clarity Moving Forward

Jeffrey Hanke
CSO & EVP, Research & Development
Tesaro

Israel Lowy
VP, Clinical Sciences & Head of Translational Oncology
Regeneron

David McDermott
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center

Amy Peterson
CMO, Immuno-Oncology
BeiGene

Corinne Reimer
Associate Director, In Vivo Pharmacology
AstraZeneca

Kurt Schalper
Assistant Professor of Pathology & Medicine
Yale School of Medicine

Beth Trehu
CMO
Jounce

Bob Uger
CSO
Trillium Therapeutics

Day Two

Wednesday, March 21 2018

15.00 | Examining CD47 as a Novel Immune Checkpoint Pathway

Yan Lan
Director, Translational Immunology
EMD Serono

Day Two

Wednesday, March 21 2018

14.30 | Enhancing Anti-Tumor Immune Responses Through Bifunctional Immune-Checkpoint Targeting Therapeutics

Roger Dansey
SVP, Global Clinical Development Oncology
Merck

Day One

Tuesday, March 20 2018

09.00 | Keynote: Enhancing Patient Outcomes With Pembrolizumab In Combination Strategies

Bill Grossman
Group Medical Director, Cancer Immunotherapy
Genentech

Day One

Tuesday, March 20 2018

09.30 | Keynote: Addressing the Tidal Wave of Cancer Immunotherapy Combinations Through Innovative Trial Designs

Lata Jayaraman
Head of Tumor Immunotherapy
Seres Therapeutics

Jason Luke
Assistant Professor of Medicine
University of Chicago

Day One

Tuesday, March 20 2018

16.00 | Tumor & Host Factors Influencing the Tumor Microenvironment & Response to Checkpoint Blockade

Shuji Ogino
Professor & Chief of Program in MPE Molecular Pathological Epidemiology
Dana-Farber Cancer Institute

Rodney Prell
Principal Scientist, Toxicologist & Cancer Immunotherapy Area Lead
Genentech

Bonnie Rup
Biopharmaceutical Consultant
Bonnie Rup Consulting

Tim Sullivan
VP, Business Development
Arcus Biosciences

Shannon Turley
Principal Scientist, Cancer Immunology
Genentech

Day One

Tuesday, March 20 2018

16.30 | Evaluating the Role of Stromal Cells & TGFβ Signalling in the Resistance to Atezolizumab

Jianda Yuan
Director, Translational Immuno-Oncology Research & Early Clinical Development
Merck

Day Two

Wednesday, March 21 2018

09.30 | Keynote Panel Discussion: Dissecting Recent Clinical Successes and Failures to Give Greater Clarity Moving Forward

Scott Bultman
Associate Professor, Genetics
UNC School of Medicine

Bernard Fox
Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology
Providence Cancer Center

Day One

Tuesday, March 20 2018

17.00 | Chair’s Closing Remarks

08.15 | Chair’s Opening Remarks

Day Two

Wednesday, March 21 2018

15.30 | Chair’s Closing Remarks

08.30 | Keynote: Investigating Crucial Factors That Determine the Success of Immune Checkpoint Combinations

08.25 | Chair’s Opening Remarks

Ashok Gupta
VP, Immuno-Oncology
MedImmune

Day Two

Wednesday, March 21 2018

09.30 | Keynote Panel Discussion: Dissecting Recent Clinical Successes and Failures to Give Greater Clarity Moving Forward

Barbara Joyce-Shaikh
Associate Principal Scientist
Merck

Jennifer Mataraza
Senior Investigator ll, Group Leader, Translational Immuno-Oncology
Novartis

Mark Paris
Assistant Director, Translational Applications
Mitra Biotech

Osama Rahma
Assistant Professor of Medicine
Dana-Farber Cancer Institute

Catherine Sabatos-Peyton
Director
Novartis

Day Two

Wednesday, March 21 2018

09.30 | Keynote Panel Discussion: Dissecting Recent Clinical Successes and Failures to Give Greater Clarity Moving Forward

Anna Tafuri
Global Early Clinical Lead
Bayer

Chris Turner
VP, Clinical Science
Celldex Therapeutics